PharmacoEconomics & Outcomes News 680 - 15 Jun 2013 TAVI cost effective in severe AS in the UK Transcatheter aortic-valve implantation (TAVI) is a cost-effective option in elderly patients with severe aortic stenosis (AS) who are at high operative risk, compared with surgical aortic-valve replacement (SAVR), from a UK healthcare provider perspective. This is the main finding of a study that used a cohort Markov model to compare the costs and outcomes of TAVI with those of SAVR using outcomes data from a randomised US trial, QOL data from a UK population with AS, and cost data (2011 prices) based on national UK values. The model showed that TAVI provided marginal QALY gains per person at 10 years, compared with SAVR (2.81 vs 2.75), at slightly lower total 10-year costs (£52 593 vs £53 943). Although the unit cost of TAVI was substantially higher (£16 500 vs £9256), SAVR incurred greater length of hospital stay and time in intensive care, which were significant cost drivers. The base-case results were robust to changes in input parameters according to numerous sensitivity analyses. Probabilistic sensitivity analyses showed that TAVI had a 64.6% likelihood of being cost effective, compared with 35.4% for SAVR, at the NICE willingness-to-pay threshold of £20 000/QALY gained. Fairbairn TA, et al. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. Heart : 21 May 2013. Available from: URL: http:// dx.doi.org/10.1136/heartjnl-2013-303722 803088077 1 PharmacoEconomics & Outcomes News 15 Jun 2013 No. 680 1173-5503/10/0680-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

TAVI cost effective in severe AS in the UK

Download PDF Report

Upload
lillian-turner
View
215
Download
2

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 680 - 15 Jun 2013

TAVI cost effective in severe AS inthe UK

Transcatheter aortic-valve implantation (TAVI) is acost-effective option in elderly patients with severeaortic stenosis (AS) who are at high operative risk,compared with surgical aortic-valve replacement(SAVR), from a UK healthcare provider perspective.

This is the main finding of a study that used a cohortMarkov model to compare the costs and outcomes ofTAVI with those of SAVR using outcomes data from arandomised US trial, QOL data from a UK populationwith AS, and cost data (2011 prices) based on nationalUK values.

The model showed that TAVI provided marginal QALYgains per person at 10 years, compared with SAVR (2.81vs 2.75), at slightly lower total 10-year costs (£52 593 vs£53 943). Although the unit cost of TAVI wassubstantially higher (£16 500 vs £9256), SAVR incurredgreater length of hospital stay and time in intensive care,which were significant cost drivers. The base-caseresults were robust to changes in input parametersaccording to numerous sensitivity analyses. Probabilisticsensitivity analyses showed that TAVI had a 64.6%likelihood of being cost effective, compared with 35.4%for SAVR, at the NICE willingness-to-pay threshold of£20 000/QALY gained.Fairbairn TA, et al. The cost-effectiveness of transcatheter aortic valveimplantation versus surgical aortic valve replacement in patients with severe aorticstenosis at high operative risk. Heart : 21 May 2013. Available from: URL: http://dx.doi.org/10.1136/heartjnl-2013-303722 803088077